ORIGINAL RESEARCH article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1564826
This article is part of the Research TopicFormation of Immunological Niches in Tumor Microenvironments: Mechanisms and Therapeutic PotentialView all 31 articles
CHMP6 as a Novel Prognostic Biomarker in Bladder Cancer: Insights from a Comprehensive Cell Death-Related Gene Risk Model
Provisionally accepted
- 1Air Force Medical University, Xi'an, China
- 2ShanghaiTech University, Shanghai, Shanghai Municipality, China
- 3Department of Pathology, Xijing Hospital, Air Force Medical University, Xi'an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Bladder cancer (BLCA) is a prevalent and aggressive disease characterized by substantial molecular heterogeneity, complicating its diagnosis and treatment. Existing therapies, including surgery and chemotherapy, often lack specificity. Alterations in cell death mechanisms, such as ferroptosis, cuproptosis, and immunogenic cell death, significantly impact cancer progression and prognosis. We analyzed gene expression data from TCGA and GEO. Cox regression analyses generated a prognostic risk score model incorporating LIPT1, ACSL5, and CHMP6. This model successfully stratified BLCA patients into different risk categories and was validated through survival analysis, immune infiltration, mutation burden assessment, drug sensitivity predictions, and single-cell analysis. The high-risk group was linked to differentiation processes, developmental stages, and active metabolic pathways. Experimental validation highlighted CHMP6's role in enhancing BLCA cell survival and migration by regulating the cell cycle. The model's prognostic relevance was further supported by drug sensitivity and immune metrics.These results provide valuable insights into potential biomarkers and therapeutic targets for BLCA treatment.
Keywords: CHMP6, BLCA, CDRI, ICD, ferroptosis
Received: 22 Jan 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Ning, Wu, Yang, Hou, Liu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wei Ning, Air Force Medical University, Xi'an, China
Chang-Bin Yang, Air Force Medical University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.